Stereospecific ligands and their complexes. IV: Synthesis, characterization and cytotoxicity of novel platinum(IV) complexes with ethylenediamine-N,N′-di-S,S-2-propanoate and halogenido ligands: Crystal structure of s-cis-[Pt(S,S-eddp)Cl2]·4H2O and uns-cis-[Pt(S,S-eddp)Br2]

[1]  M. Hall,et al.  Basis for design and development of platinum(IV) anticancer complexes. , 2007, Journal of medicinal chemistry.

[2]  T. Stanojković,et al.  Activity of some platinum(II/IV) complexes with edda-type ligands against human adenocarcinoma HeLa cells , 2006 .

[3]  M. Galanski,et al.  Synthesis and structure-activity relationships of mono- and dialkyl-substituted oxaliplatin derivatives. , 2005, European journal of medicinal chemistry.

[4]  V. Trajković,et al.  Novel platinum(IV) complexes induce rapid tumor cell death in vitro , 2005, International journal of cancer.

[5]  M. Jakupec,et al.  Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. , 2005, Current medicinal chemistry.

[6]  T. Stanojković,et al.  Syntheses and activity of some platinum(IV) complexes with N-methyl derivate of glycine and halogeno ligands against HeLa, K562 cell lines and human PBMC , 2005 .

[7]  T. Stanojković,et al.  Activity of some platinum(II/IV) complexes with O,O-n-butyl-and O,O-n-pentyl-ethylenediamine-N,N'-di-3-propanoate and halogeno ligands against HeLa and K562 cell lines and human PBMC. , 2005, Journal of inorganic biochemistry.

[8]  G. Bogdanović,et al.  Aerosol synthesis of pure and Pt-doped ZnO particles using nitrate and pdda-Pt(IV) complex solutions , 2005 .

[9]  M. Jakupec,et al.  Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. , 2004, European journal of medicinal chemistry.

[10]  G. Bogdanović,et al.  Synthesis and crystal structure of trans-dichloro(1,3-propylenediamine-n,n′-diacetato)platinum(IV) monohydrate , 2004 .

[11]  F. Heinemann,et al.  Complex compounds of platinum(IV) and O,O-dialkyl-ethylenediamine-N,N′-di-3-propanoate ligands. A structural evidence for geometry of hydrolytic product of some esters , 2004 .

[12]  M. Jakupec,et al.  Recent developments in the field of tumor-inhibiting metal complexes. , 2003, Current pharmaceutical design.

[13]  M. Hall,et al.  Platinum(IV) antitumour compounds: their bioinorganic chemistry , 2002 .

[14]  G. Kaluđerović,et al.  Synthesis and characterization of the cobalt(III) complexes with ethylenediamine-N,N′-di-3-propanoate ligand and its esters , 2002 .

[15]  S. Trifunović,et al.  TRANSITION METAL COMPLEXES WITH EDDA-TYPE LIGANDS—A REVIEW , 2002 .

[16]  G. Bogdanović,et al.  Synthesis and Crystal Structure of trans-Dichloro(Ethylenediamine- -N,N′-DI-3-Propionato)Platinum(IV) Monohydrate , 2002 .

[17]  L. Kèlland,et al.  Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents. Crystal and molecular structure of [PtL4CL2].H20 where L4 is ethylenediamine-N,N'-diacetate. , 2001, Journal of inorganic biochemistry.

[18]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[19]  M. Nardelli,et al.  PARST95 – an update to PARST: a system of Fortran routines for calculating molecular structure parameters from the results of crystal structure analyses , 1995 .

[20]  David A. Brown,et al.  Synthesis of trans-bis (glycinehydroxamato) platinum (II) hydrate tans-dichlorobis (glycylglycine) platinum (II) dihydrate and the crystal and molecular structures of trans-dichlorobis (glycine) platinum (II) dihydrate and trans, trans-dichlorobis (glycinato) platinum (IV), hydrolysis products forme , 1995 .

[21]  Giovanni Luca Cascarano,et al.  Completion and refinement of crystal structures with SIR92 , 1993 .

[22]  R. Larsen,et al.  Nuclear magnetic resonance investigation of the hydrogen peroxide oxidation of platinum(II) complexes. Crystal and molecular structures of sodium trans-dihydroxobis(malonato)platinate(IV) hexahydrate and sodium trans-dihydroxobis(oxalato)platinate(IV) hexahydrate , 1993 .

[23]  D. A. Flick,et al.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. , 1984, Journal of immunological methods.

[24]  D. Radanović.  Optical activity of cobalt(III), chromium(III) and rhodium(III) complexes with aminopolycarboxylate EDTA-type and related ligands , 1984 .

[25]  B. Douglas,et al.  Circular dichroism studies of some cobalt(III) complexes which contain phenyl-substituted ethylenediamine-N,N'-diacetate analogs , 1979 .

[26]  P. Garnett,et al.  Ethylenediaminediacetate complexes of cobalt(III). Part I. The preparations and configurations of some ethylenediamine-N,N′-diacetate cobalt(III) complexes , 1974 .

[27]  G. R. Brubaker,et al.  Complexes of cobalt(III) with flexible tetradentate ligands , 1971 .

[28]  K. Nakamoto.  Infrared spectra of inorganic and coordination compounds , 1970 .

[29]  J. Sudmeier,et al.  Nuclear magnetic resonance studies of rate and mechanism of stereospecific acid- and base-catalyzed deuterations of .alpha.-hydrogen atoms in ethylenediamine-N,N1-diacetatocobalt(III) chelates , 1968 .

[30]  C. F. Liu,et al.  Nuclear magnetic resonance determination of the absolute configuration of complexes of cobalt(III) with asymmetric tetradentate ligands , 1968 .

[31]  C. Liu.  Complexes of Ethylenediamine-N,N'-diacetic Acid and Platinum.cis-Oxidation , 1964 .